A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2
100
about 5.3 years
18–80
4 sites in CA, MO, NC +1
About this study
This trial is testing whether adding venetoclax to a Bruton Tyrosine Kinase Inhibitor (BTKi) pill improves outcomes for people with CLL or SLL. Participants will continue their current BTKi treatment as long as it's working, or they may receive the BTKi plus venetoclax for one year. After that period, both pills would be stopped and participants will be closely monitored.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Ibrutinib, Acalabrutinib, Zanubrutinib
- 2.Take Venetoclax
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
acalabrutinib, ibrutinib, venetoclax, zanubrutinib
oral (Oral Tablet), oral (Oral Capsule), oral
Primary: The primary objective is to evaluate complete response (CR) rate, per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, 2018
Secondary: CLL/SLL patients' experience through patient reported outcome (PRO) QoL, CLL/SLL patients' experience through patient reported outcome (PRO) measures of fatigue (a key secondary objective), Measure financial toxicity (FT) in CLL/SLL patients, Overall response rate (ORR), per the International Workshop on Chronic Lymphocytic Leukemia (iwCLL) criteria, 2018., Safety and adverse events, measured by Common Terminology Criteria for Adverse Events (CTCAE).
Oncology